<DOC>
	<DOCNO>NCT01423526</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics orally administrate DWP10292 healthy male volunteer .</brief_summary>
	<brief_title>A Single Dose Study DWP10292 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>A subject provide write informed consent participate study cooperative regard compliance study related constraint Healthy adult male subject age 20 45 year The subject Body weight ≥ 60 kg &lt; 90 kg Body Mass Index ( BMI ) ≥ 18.5 kg/m2 &lt; 27.0 kg/m2 A Subject judge healthy investigator participate study base screen result ( accord standard reference index update recently ) A subject sign symptom previously diagnose disease liver ( viral hepatitis ) , digestive system , cardiovascular , kidney , respiratory , endocrinology , neurology , immune system , hematology , psychology function significant diseases history suspicion current drug abuse alcohol abuse A subject show vital sign number systolic blood pressure ≥140 mmHg ≤100 mmHg , number diastolic blood pressure ≥90mmHg ≤60mmHg A subject show follow result clinical laboratory test : AST , ALT &gt; 1.25 time upper limit normal range QTc &gt; 430msec T.bil &gt; 1.25 time upper limit normal range A subject 400mL blood sample ( whole blood plasma donation , etc . ) within last 8 week Subject take clinical licensed medication another clinical trial within 8week period prior first administration study medication ( The last administration medication consider end point previous clinical trial ) . Subject smokes average 10 cigarettes/day unable quit smoke clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>